Edge Rewrite
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a247f2b758b26c75

Jump to content

// Workers AI · dad joke modeWhat did Hydroxyethylrutoside say? "I've got a fluid relationship

From Wikipedia, the free encyclopedia
(Redirected from Venoruton)

Hydroxyethylrutosidesis (oxerutins, O-beta-hydroxyethyl-rutosides, HR, or HER) are hydroxyethyl derivatives of rutosides. Examples include:

Oxerutins are semisynthetic derivatives of plant constituents. Although they are closely related to the natural flavonoid rutin, hydroxyethylrutosides are not found in food. The only way to take them is in a supplement.[1]

Health benefits

[edit]

Relvène (1967 French version), Venoruton (1962 Swiss version), and Paroven are mixtures of hydroxyethyl rutinosides. Hydroxyethylrutosides are used in the treatment of chronic venous insufficiency[2] and hypertensive microangiopathy.[3] Oxerutins work by reducing leakage from the small blood vessels (capillaries).[4]

Hydroxyethylrutosides have been used as an alternative to horse chestnut preparations (venostasin) containing aescin. Typical doses are in the order of 1,000 mg/day.[5]

Effects of hydroxyethylrutosides against adriamycin-induced toxicity have been investigated in rats.[6]

References

[edit]
  1. Oxerutins on healthlibrary.epnet.com
  2. Frick, RW (2000). "Three treatments for chronic venous insufficiency: Escin, hydroxyethylrutoside, and Daflon". Angiology. 51 (3): 197–205. doi:10.1177/000331970005100303. PMID 10744007. S2CID 19421726.
  3. Incandela, L; Belcaro, G; Renton, S; Desanctis, MT; Cesarone, MR; Bavera, P; Ippolito, E; Bucci, M; et al. (2002). "HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: A prospective, placebo-controlled, randomized trial". Journal of Cardiovascular Pharmacology and Therapeutics. 7 (Suppl 1): S7–S10. doi:10.1177/107424840200700103. PMID 12011966. S2CID 9720685.
  4. Paroven on netdoctor.co.uk, archived from the original on 2009-03-27, retrieved 2009-09-21
  5. The handbook of clinically tested herbal remedies, Volume 2 by Marilyn Barrett
  6. Gulati, OP; Nordmann, H; Aellig, A; Maignan, MF; McGinness, J (1985). "Protective effects of O-(beta-hydroxyethyl)-rutosides (HR) against adriamycin-induced toxicity in rats". Archives Internationales de Pharmacodynamie et de Thérapie. 273 (2): 323–34. PMID 4004421.
[edit]